Pasithea Therapeutics Past Earnings Performance
Past criteria checks 0/6
Pasithea Therapeutics's earnings have been declining at an average annual rate of -53.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-53.8%
Earnings growth rate
-40.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -88.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Pasithea Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -16 | 7 | 9 |
| 30 Jun 24 | 0 | -16 | 8 | 9 |
| 31 Mar 24 | 0 | -16 | 8 | 9 |
| 31 Dec 23 | 0 | -16 | 8 | 8 |
| 30 Sep 23 | 0 | -15 | 9 | 6 |
| 30 Jun 23 | 0 | -15 | 9 | 6 |
| 31 Mar 23 | 0 | -14 | 10 | 4 |
| 31 Dec 22 | 0 | -12 | 10 | 3 |
| 30 Sep 22 | 0 | -7 | 9 | 1 |
| 30 Jun 22 | 0 | -4 | 8 | 0 |
| 31 Mar 22 | 0 | -3 | 6 | 0 |
| 31 Dec 21 | 0 | -2 | 5 | 0 |
| 30 Sep 21 | 0 | -3 | 3 | 0 |
Quality Earnings: KTTA is currently unprofitable.
Growing Profit Margin: KTTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KTTA is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.
Accelerating Growth: Unable to compare KTTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KTTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KTTA has a negative Return on Equity (-88.46%), as it is currently unprofitable.